10-Q: Nutriband Reports Declining Revenue Amidst Development Efforts

Nutriband Inc. filed its quarterly report for the period ending July 31, 2026, revealing a decrease in revenue and continued net losses, though progress is noted in its Aversa Fentanyl product development.

Summary

• Nutriband Inc. reported revenues of $437,514 for the three months ended July 31, 2026, a decrease from $622,452 in the same period last year. For the six months ended July 31, 2026, revenues were $870,913, down from $1,289,884 in the prior year.
• The company incurred net losses of $880,561 for the three-month period and $2,122,517 for the six-month period ended July 31, 2026.
• Selling, general, and administrative expenses decreased to $750,317 for the three months and $1,954,208 for the six months, compared to the prior year periods.
• Research and development expenses for the Aversa Fentanyl product also decreased, to $322,194 for the three months and $569,455 for the six months.
• The company has $3,421,615 in cash and cash equivalents as of July 31, 2026.
• A lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP is ongoing, with the company denying allegations and pursuing counterclaims.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to declining revenues, significant net losses, and ongoing legal proceedings, despite some progress in product development.

Positives

• Gross profit margin increased due to a higher margin sales mix in the Pocono Pharmaceuticals segment.
• Selling, general, and administrative expenses saw a reduction in both the three-month and six-month periods compared to the prior year.
• Research and development expenses for the Aversa Fentanyl product decreased, indicating potential cost efficiencies.
• The company has a substantial cash balance of $3,421,615 as of July 31, 2026, providing some operational runway.
• Progress continues on the Aversa Fentanyl product development, with an agreement with Kindeva Drug Delivery for commercial manufacturing process development.

Negatives

• Revenue decreased significantly in both the three-month and six-month periods compared to the prior year.
• The company reported substantial net losses for both the three-month ($880,561) and six-month ($2,122,517) periods.
• The decrease in revenue for the Pocono Pharmaceuticals segment is attributed to a principal customer moving operations to Asia, with a further decrease expected.
• There were no sales from the 4P Therapeutics segment in the current year due to a shift in focus and contract wind-down.
• The company's disclosure controls and procedures were found to be not effective, with material weaknesses identified in internal controls.
• A significant legal proceeding with Joseph Gunnar, LLC and Lucosky Brookman LLP is ongoing, seeking substantial damages.

Risks

• The United States is involved in a war with Iran, which could adversely affect domestic and international markets, tariffs, and healthcare products.
• Global financial and economic conditions, including current stock market trends and economic policies, could materially affect liquidity, capital resources, and the ability to raise additional capital.
• Inflationary factors may adversely affect operating results by increasing costs for products, rights, and overhead.
• The company is subject to risks common to low-revenue start-up enterprises, including undercapitalization and cash shortages.
• Drug development companies incur substantial losses during development and FDA testing, with no assurance of profitability or FDA approval.
• The company has not completed the development of its lead product, Aversa Fentanyl, and has no product currently marketable in the United States.
• Delays in regulatory review and approval, or requirements for additional studies, could increase expenses and delay product approval.
• The drug delivery industry is subject to rapid technological change, and failure to keep pace could render products obsolete.

Future Outlook

The company's revenue is expected to decrease in the balance of the current year due to a principal customer moving operations to Asia. The company continues to focus on the development of its Aversa Fentanyl product and other transdermal pharmaceutical products. Management believes that sufficient funds will be generated from operations to fund operations for one year from the filing date, indicating improved operations and the ability to continue as a going concern.

Management Comments

• Management believes that sufficient funds will be generated from operations to fund its operations for one year from the date of the filing of these condensed consolidated financial statements, which indicates improved operations and the Companys ability to continue operations as a going concern.
• Management believes the substantial doubt about the ability of the Company to continue as a going concern is alleviated by the above assessment.

Industry Context

StockSavvy.ai notes that Nutriband operates in the highly competitive and regulated pharmaceutical and drug delivery industry. The focus on transdermal patches and abuse-deterrent technology aligns with industry trends aimed at improving drug safety and patient compliance. However, the significant revenue decline and ongoing legal challenges highlight the inherent risks and long development cycles typical of this sector.

Comparison to Industry Standards

• The company's revenue decline in the Pocono Pharmaceuticals segment, attributed to a major customer relocating, is a concern. Many contract manufacturing organizations (CMOs) rely on a few key clients, making such shifts impactful.
• The ongoing net losses are typical for early-stage drug development companies, but the magnitude and the identified material weaknesses in internal controls are red flags.
• The legal proceedings with Joseph Gunnar, LLC and Lucosky Brookman LLP are a significant distraction and potential financial drain, which is not uncommon in the industry but requires careful management.
• The company's reliance on equity financing and warrants for funding is a common strategy for biotech/pharma startups, but it leads to potential dilution for existing shareholders.

Corporate Governance

Legal Proceedings

• Lawsuit initiated by Joseph Gunnar, LLC and Lucosky Brookman LLP alleging breach of contract, fraudulent activities, and tortious interference, seeking over $500,000 in damages plus punitive damages and legal fees.
• Nutriband has filed counterclaims against Joseph Gunnar & Co. for intentional interference and breach of fiduciary duty, seeking $1,000,000 for each claim and a declaratory judgment.
• The case is currently in the discovery stage with no pending hearings or motions.

Related Party Transactions

• During the six months ended July 31, 2026, a director and a related party were issued warrants to purchase 206,080 shares of common stock at an exercise price of $3.73 per share.
• During the six months ended July 31, 2025, a director and a related party exercised warrants and were issued shares of common stock.

Stakeholder Impact

• Shareholders may experience further dilution due to ongoing need for capital raises and the exercise of outstanding options and warrants.
• Investors may be concerned by the declining revenues, continued net losses, and identified material weaknesses in internal controls.
• The ongoing legal proceedings could result in significant financial costs and divert management attention, potentially impacting future performance.

Next Steps

• Continue product development for Aversa Fentanyl and other abuse-deterrent transdermal products.
• Complete development of chemistry, manufacturing, and controls (CMC) information for Aversa Fentanyl to support an NDA.
• Address the ongoing legal proceedings with Joseph Gunnar, LLC and Lucosky Brookman LLP.
• Continue to manage internal control deficiencies and improve financial reporting processes.

Key Dates

Recommendation

While the company is making progress in its product development pipeline, the significant decline in revenue, continued substantial net losses, and identified material weaknesses in internal controls present considerable risks. The ongoing legal battle also adds uncertainty. The current cash position provides some buffer, but without a clear path to profitability or market-approved products, a 'hold' recommendation is prudent, awaiting further developments and resolution of key challenges.

Keywords

transdermal patches, drug delivery, abuse deterrent technology, AVERSA, Fentanyl, Pocono Pharmaceuticals, 4P Therapeutics, contract manufacturing